Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy

22Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Pretreatment and on-treatment plasma cytokine levels in predicting clinical benefit in patients with advanced non-small cell lung cancer (NSCLC) treated with anti-programmed death-1 (PD-1)-based chemotherapy is still a matter of debate. Methods: We measured 12 kind of plasma cytokines in patients with stage III/IV NSCLC before and during treatment with anti-PD-1 based chemotherapy. Associations with best overall response, and survival including progression-free survival (PFS) and overall survival (OS) were assessed using Chi-square test and Kaplan–Meier plots with log-rank test, respectively. Logistic regression and Cox regression were used to determine independent risk factors. Results: Of a total of 60 patients, high-level of pretreatment interleukin-2 was associated with longer PFS (log rank p = 0.049), while high-level of pretreatment interleukin-8 was associated with shorter OS (log rank p = 0.006). Increased on-treatment interleukin-1β (IL-1β) was associated with both better response (odds ratio [OR] 6.233, 95% confidential interval [CI]: 1.451–26.344, p = 0.013) and longer PFS (hazard ratio [HR] 0.305, 95% CI: 0.127–0.730, p = 0.008). On the contrary, increased on-treatment interleukin-6 (IL-6) was associated with a worse response (OR 0.015, 95% CI: 0.001–0.400, p = 0.012), worse PFS (HR 2.639, 95% CI: 1.163–5.991, p = 0.020) and worse OS (HR 2.742, 95% CI: 1.063–7.074, p = 0.037). Increased interferon-γ (IFN-γ) was found to be associated with better PFS (HR 0.336, 95% CI: 0.153–0.745, p = 0.007). Conclusions: In patients with advanced NSCLC who received chemoimmunotherapy, on-treatment increased IL-1β and IFN-γ may serve as positive indicator of efficacy, while on-treatment increased IL-6 might play a predictive role of worse clinical outcome.

Cite

CITATION STYLE

APA

Shi, Y., Liu, X., Du, J., Zhang, D., Liu, J., Chen, M., … Wang, M. (2022). Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thoracic Cancer, 13(2), 219–227. https://doi.org/10.1111/1759-7714.14248

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free